Want to see GB:TRUE full AI Analyst Report?
Top Page
Braveheart Investment
(LSE:TRUE)
Select Model
Select Model
Rating:44Neutral
Price Target:
3.00 p
▲(62.16% Upside)
Action:Reiterated
Date:07/04/26
The score is primarily held down by weak financial performance—shrinking revenue, persistent operating losses, and ongoing cash burn—despite a relatively low-debt balance sheet. Technicals are mixed (positive MACD but softer short-term trend and neutral-to-weak RSI), and valuation is constrained by loss-making results (negative P/E) with no dividend yield data to offset risk.
Positive Factors
Low financial leverage
A near-zero reported debt load is a durable balance-sheet strength: it reduces default and interest-rate risk, preserves flexibility to support portfolio companies or fund operations, and buys time for realisations. This structural buffer matters during prolonged investment cycles.
Negative Factors
Collapsing revenue & weak operating results
Sustained revenue collapse and repeated operating losses indicate structural weakness in the company's core ability to generate recurring top-line and operating profits. Over months this undermines reinvestment capacity, raises dependence on non‑operating gains, and strains long-term viability.
Read all positive and negative factors
Positive Factors
Negative Factors
Low financial leverage
A near-zero reported debt load is a durable balance-sheet strength: it reduces default and interest-rate risk, preserves flexibility to support portfolio companies or fund operations, and buys time for realisations. This structural buffer matters during prolonged investment cycles.
Read all positive factors
Braveheart Investment (TRUE) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£2.47M
Dividend YieldN/A
Average Volume (3M)158.03K
Price to Earnings (P/E)―
Beta (1Y)0.18
Revenue GrowthN/A
EPS Growth68.42%
CountryUK
Employees5
SectorFinancial
Sector Strength70
IndustryInvestment - Banking & Investment Services
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding78,473,490
10 Day Avg. Volume114,553
30 Day Avg. Volume158,033
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Braveheart Investment Business Overview & Revenue Model
Company Description
Truetide plc is a private equity and venture capital firm specializing in loan, mezzanine, seed/startup, early venture, late stage, emerging growth, turnaround, distress situations, buyout and growth capital companies. It prefers to invest in mate...
How the Company Makes Money
Braveheart generally makes money through (1) returns on its investment portfolio and (2) investment/management-related fees earned via its operating subsidiaries.
1) Investment returns (core driver): The company invests in early-stage and growth ...
Braveheart Investment Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
14
Very Negative
| Breakdown | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 128.75K | 20.50K | 60.90K | 50.90K | 78.13K |
| Gross Profit | 60.32K | -274.18K | -366.56K | -505.24K | -558.01K |
| EBITDA | -421.87K | -565.91K | -811.88K | -788.22K | -695.49K |
| Net Income | -424.97K | -1.09M | -7.25M | 1.58M | 1.88M |
Balance Sheet | |||||
| Total Assets | 2.32M | 2.39M | 3.50M | 11.61M | 7.06M |
| Cash, Cash Equivalents and Short-Term Investments | 150.60K | 63.67K | 1.74M | 934.86K | 1.85M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 108.21K | 58.14K | 104.14K | 1.09M | 449.86K |
| Stockholders Equity | 2.22M | 2.33M | 3.40M | 10.52M | 6.63M |
Cash Flow | |||||
| Free Cash Flow | 0.00 | -541.01K | -736.12K | -768.19K | -1.28M |
| Operating Cash Flow | -536.99K | -541.01K | -736.12K | -768.19K | -1.27M |
| Investing Cash Flow | 344.32K | -1.14M | 1.54M | -1.08M | -1.40M |
| Financing Cash Flow | 279.59K | 0.00 | 0.00 | 930.36K | 2.42M |
Braveheart Investment Technical Analysis
Neutral
1.85
Price Trends
2.95
Positive
2.46
Positive
2.29
Positive
Market Momentum
0.09
Positive
41.37
Neutral
13.41
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:TRUE, the sentiment is Neutral. The current price of 1.85 is below the 20-day moving average (MA) of 3.46, below the 50-day MA of 2.95, and below the 200-day MA of 2.29, indicating a neutral trend. The MACD of 0.09 indicates Positive momentum. The RSI at 41.37 is Neutral, neither overbought nor oversold. The STOCH value of 13.41 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GB:TRUE.
Braveheart Investment Peers Comparison
UnderperformOutperform
Sector (68)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% | |
52 Neutral | £252.00K | -4.67 | ― | ― | ― | ― | |
50 Neutral | £4.54M | 4.74 | -12.33% | ― | -106.88% | -66.67% | |
44 Neutral | £2.47M | -1.94 | -37.63% | ― | ― | 68.42% | |
42 Neutral | £1.48M | <0.01 | -20.48% | ― | ― | ― | |
41 Neutral | £2.43M | -1.68 | -140.34% | ― | ― | 83.53% |
* Financial Sector Average
GB:TRUE
Braveheart Investment
3.15
0.80
34.04%
GB:BLU
Blue Star Capital
4.75
-15.75
-76.83%
GB:GUN
Gunsynd
0.10
-0.04
-25.93%
GB:PRIM
Primorus Investments
3.65
0.50
15.87%
GB:VOX
Vertu Capital
0.18
0.00
0.00%
Braveheart Investment Corporate Events
Business Operations and StrategyFinancial DisclosuresShareholder Meetings
Truetide Narrows Loss as Portfolio Diagnostics and Industrial Holdings Gain Traction
Positive
Jul 1, 2026
Truetide plc reported a sharply reduced pre-tax loss of £425,000 for the year to 31 March 2026, down from £1.09 million, as its listed-investments NAV reached 3.7p per share despite Paraytec still being carried at nil value. Portfolio co...
Business Operations and Strategy
Truetide’s Paraytec Moves Toward Breath-Based Lung Cancer Screening Deal with VosBio
Positive
Jun 25, 2026
Truetide’s investee company Paraytec has agreed heads of terms with U.S.-based VosBio Inc. for a proposed research collaboration to explore a non-invasive early lung cancer test. The partners will combine VosBio’s Universal Breath Coll...
Business Operations and StrategyExecutive/Board Changes
Truetide CEO Steps Down from Autins Board but Retains Key Investor Rights
Neutral
Jun 24, 2026
Truetide plc, the AIM-quoted investment company formerly known as Braveheart Investment Group, has announced that its chief executive Trevor Brown has stepped down as a Non-Executive Director of Autins Group with immediate effect. Despite the boar...
Business Operations and StrategyProduct-Related Announcements
Truetide’s Paraytec Hits Alpha‑Synuclein Milestone With CX300 Diagnostic Platform
Positive
May 21, 2026
Truetide’s investee Paraytec has completed the proof-of-concept phase for an alpha-synuclein assay on its CX300 platform, demonstrating the system’s ability to measure aggregation kinetics relevant to synucleinopathies such as Parkinso...
Regulatory Filings and Compliance
Truetide CEO Trevor Brown Trims Stake as Concert Party Nears 30% Ownership
Neutral
May 19, 2026
Truetide plc has disclosed that Chief Executive Trevor Brown sold 7,500 ordinary shares at 2.7 pence each on 18 May 2026, a small disposal that slightly reduces his personal stake. Following this transaction, Brown’s beneficial holding stand...
Regulatory Filings and Compliance
Truetide CEO Trevor Brown Lifts Stake to Over 28% with Market Share Purchase
Positive
May 8, 2026
Truetide plc disclosed that Chief Executive Trevor Brown purchased 175,000 ordinary shares in the company on 7 May 2026 at a price of 1.9 pence per share on the AIM market. Following this transaction, Brown’s beneficial holding rose to 22,14...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.